Literature DB >> 14991225

Differential autoreceptor control of extracellular 5-HT in guinea pig and rat: species and regional differences.

Zoë A Hughes1, Lee A Dawson.   

Abstract

RATIONALE: Central 5-hydroxytryptamine (5-HT) release is regulated by inhibitory 5-HT autoreceptors, including 5-HT(1A) and 5-HT(1B) receptors.
OBJECTIVES: The purpose of this study was to use combinations of selective autoreceptor antagonists to elucidate the role of these receptors in controlling extracellular 5-HT in terminal areas. METHODS. Microdialysis was carried out in awake rats and guinea pigs to measure extracellular 5-HT in the frontal cortex and dentate gyrus. Using the selective 5-HT(1A) receptor antagonist, WAY-100635, and the selective 5-HT(1B) receptor antagonist, SB-224289, we have compared the roles of 5-HT(1A) and 5-HT(1B) autoreceptors in controlling extracellular 5-HT.
RESULTS: SB-224289 (4 mg/kg i.p.) alone produced a significant 50% increase in extracellular 5-HT in the dentate gyrus of guinea pigs, but not in the frontal cortex of the same animals. Co-administration of WAY-100635 (0.3 mg/kg s.c.), did not change the SB-224289-induced increase in dentate gyrus 5-HT but did produce a significant augmentation (60% increase) of guinea pig frontal cortex 5-HT. In contrast, neither autoreceptor antagonist, alone or in combination, affected extracellular 5-HT in the frontal cortex or dentate gyrus of rats.
CONCLUSIONS: These data indicate that there is a species difference in the autoreceptor control of 5-HT release. Furthermore, in the guinea pig there is a divergence between dorsal and median raphe innervated brain regions. On the basis that antagonism of 5-HT(1A) and 5-HT(1B) receptors produced an immediate increase in extracellular 5-HT in multiple brain regions in the guinea pig, it is suggested that this might be a novel mechanism for achieving antidepressant efficacy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14991225     DOI: 10.1007/s00213-003-1615-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  42 in total

1.  The effect of SB-236057-A, a selective 5-HT1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely-moving guinea-pig.

Authors:  C Roberts; P Hatcher; J J Hagan; N E Austin; P Jeffrey; P Wyman; L M Gaster; C Routledge; D N Middlemiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-08       Impact factor: 3.000

2.  The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572.

Authors:  A Gobert; A Dekeyne; M J Millan
Journal:  Neuropharmacology       Date:  2000-07-10       Impact factor: 5.250

3.  Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors.

Authors:  A Gobert; M J Millan
Journal:  Neuropsychopharmacology       Date:  1999-08       Impact factor: 7.853

4.  Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat.

Authors:  I Hervás; C M Queiroz; A Adell; F Artigas
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

5.  Enhancement of 5-HT1B and 5-HT1D receptor antagonist effects on extracellular 5-HT levels in the guinea-pig brain following concurrent 5-HT1A or 5-HT re-uptake site blockade.

Authors:  C Roberts; D F Boyd; D N Middlemiss; C Routledge
Journal:  Neuropharmacology       Date:  1999-09       Impact factor: 5.250

6.  Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study.

Authors:  P J Shah; K P Ebmeier; M F Glabus; G M Goodwin
Journal:  Br J Psychiatry       Date:  1998-06       Impact factor: 9.319

7.  A pharmacological analysis of the 5-HT receptor mediating inhibition of 5-HT release in the guinea-pig frontal cortex.

Authors:  D N Middlemiss; M E Bremer; S M Smith
Journal:  Eur J Pharmacol       Date:  1988-11-15       Impact factor: 4.432

8.  Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists.

Authors:  J S Sprouse; G K Aghajanian
Journal:  Synapse       Date:  1987       Impact factor: 2.562

9.  Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors.

Authors:  S Hjorth; S B Auerbach
Journal:  Eur J Pharmacol       Date:  1994-08-01       Impact factor: 4.432

10.  Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness.

Authors:  M S Buchsbaum; J Wu; L E DeLisi; H Holcomb; R Kessler; J Johnson; A C King; E Hazlett; K Langston; R M Post
Journal:  J Affect Disord       Date:  1986 Mar-Apr       Impact factor: 4.839

View more
  4 in total

1.  Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat.

Authors:  M L Woolley; K A Waters; J E Gartlon; L P Lacroix; C Jennings; F Shaughnessy; A Ong; D J Pemberton; M H Harries; E Southam; D N C Jones; L A Dawson
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

2.  5-HT(1A) and 5-HT(2A) receptors in the rat dorsal periaqueductal gray mediate the antipanic-like effect induced by the stimulation of serotonergic neurons in the dorsal raphe nucleus.

Authors:  Roger L H Pobbe; Hélio Zangrossi
Journal:  Psychopharmacology (Berl)       Date:  2005-10-18       Impact factor: 4.530

3.  Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.

Authors:  Eric Southam; Jackie Cilia; Jane E Gartlon; Marie L Woolley; Laurent P Lacroix; Carol A Jennings; Jane E Cluderay; Charlie Reavill; Claire Rourke; David M Wilson; Lee A Dawson; Andrew D Medhurst; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

Review 4.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.